-DOCSTART- -X- O
Cytokines -X- _ B-Intervention
, -X- _ O
currently -X- _ O
known -X- _ O
to -X- _ O
be -X- _ O
more -X- _ O
than -X- _ O
130 -X- _ O
in -X- _ O
number -X- _ O
, -X- _ O
are -X- _ O
small -X- _ O
MW -X- _ O
( -X- _ O
< -X- _ O
30 -X- _ O
kDa -X- _ O
) -X- _ O
key -X- _ O
signaling -X- _ O
proteins -X- _ O
that -X- _ O
modulate -X- _ O
cellular -X- _ O
activities -X- _ O
in -X- _ O
immunity -X- _ O
, -X- _ O
infection -X- _ O
, -X- _ O
inflammation -X- _ O
and -X- _ O
malignancy. -X- _ O
Key -X- _ O
to -X- _ O
understanding -X- _ O
their -X- _ O
function -X- _ O
is -X- _ O
recognition -X- _ O
of -X- _ O
their -X- _ O
pleiotropism -X- _ O
and -X- _ O
often -X- _ O
overlapping -X- _ O
and -X- _ O
functional -X- _ O
redundancies. -X- _ O
Classified -X- _ O
here -X- _ O
into -X- _ O
9 -X- _ O
main -X- _ O
families -X- _ O
, -X- _ O
most -X- _ O
of -X- _ O
the -X- _ O
20 -X- _ O
approved -X- _ O
cytokine -X- _ O
preparations -X- _ O
( -X- _ O
18 -X- _ B-Intervention
different -X- _ I-Intervention
cytokines -X- _ I-Intervention
; -X- _ I-Intervention
3 -X- _ I-Intervention
pegylated -X- _ I-Intervention
) -X- _ O
, -X- _ O
all -X- _ O
in -X- _ O
recombinant -X- _ O
human -X- _ O
( -X- _ O
rh -X- _ O
) -X- _ O
form -X- _ O
, -X- _ O
are -X- _ O
grouped -X- _ O
in -X- _ O
the -X- _ O
hematopoietic -X- _ O
growth -X- _ O
factor -X- _ O
, -X- _ O
interferon -X- _ O
, -X- _ O
platelet-derived -X- _ O
growth -X- _ O
factor -X- _ O
( -X- _ O
PDGF -X- _ O
) -X- _ O
and -X- _ O
transforming -X- _ O
growth -X- _ O
factor -X- _ O
β -X- _ O
( -X- _ O
TGFβ -X- _ O
) -X- _ O
families. -X- _ O
In -X- _ O
the -X- _ O
hematopoietin -X- _ O
family -X- _ O
, -X- _ O
approved -X- _ O
cytokines -X- _ O
are -X- _ O
aldesleukin -X- _ B-Intervention
( -X- _ I-Intervention
rhIL-2 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
oprelvekin -X- _ I-Intervention
( -X- _ I-Intervention
rhIL-11 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
filgrastim -X- _ I-Intervention
and -X- _ I-Intervention
tbo-filgrastim -X- _ I-Intervention
( -X- _ I-Intervention
rhG-CSF -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
sargramostim -X- _ I-Intervention
( -X- _ I-Intervention
rhGM-CSF -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
metreleptin -X- _ I-Intervention
( -X- _ I-Intervention
rh-leptin -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
the -X- _ I-Intervention
rh-erythropoietins -X- _ I-Intervention
, -X- _ I-Intervention
epoetin -X- _ I-Intervention
and -X- _ I-Intervention
darbepoietin -X- _ I-Intervention
alfa. -X- _ I-Intervention
Anakinra -X- _ I-Intervention
, -X- _ O
a -X- _ O
recombinant -X- _ O
receptor -X- _ O
antagonist -X- _ O
for -X- _ O
IL-1 -X- _ O
, -X- _ O
is -X- _ O
in -X- _ O
the -X- _ O
IL-1 -X- _ O
family -X- _ O
; -X- _ O
recombinant -X- _ O
interferons -X- _ O
alfa-1 -X- _ B-Intervention
, -X- _ I-Intervention
alfa-2 -X- _ I-Intervention
, -X- _ I-Intervention
beta-1 -X- _ I-Intervention
and -X- _ I-Intervention
gamma-1 -X- _ I-Intervention
make -X- _ O
up -X- _ O
the -X- _ O
interferon -X- _ O
family -X- _ O
; -X- _ O
palifermin -X- _ B-Intervention
( -X- _ I-Intervention
rhKGF -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
becaplermin -X- _ I-Intervention
( -X- _ I-Intervention
rhPDGF -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
in -X- _ O
the -X- _ O
PDGF -X- _ O
family -X- _ O
; -X- _ O
and -X- _ O
rhBMP-2 -X- _ B-Intervention
and -X- _ I-Intervention
rhBMP-7 -X- _ I-Intervention
represent -X- _ O
the -X- _ O
TGFβ -X- _ O
family. -X- _ O
The -X- _ O
main -X- _ O
physicochemical -X- _ O
features -X- _ O
, -X- _ O
FDA-approved -X- _ O
indications -X- _ O
, -X- _ O
modes -X- _ O
of -X- _ O
action -X- _ O
and -X- _ O
side -X- _ O
effects -X- _ O
of -X- _ O
these -X- _ O
approved -X- _ O
cytokines -X- _ O
are -X- _ O
presented. -X- _ O
Underlying -X- _ O
each -X- _ O
adverse -X- _ O
events -X- _ O
profile -X- _ O
is -X- _ O
their -X- _ O
pleiotropism -X- _ O
, -X- _ O
potency -X- _ B-Outcome
and -X- _ I-Outcome
capacity -X- _ I-Outcome
to -X- _ I-Outcome
release -X- _ I-Outcome
other -X- _ I-Outcome
cytokines -X- _ I-Outcome
producing -X- _ I-Outcome
cytokine -X- _ I-Outcome
‘cocktails’. -X- _ I-Outcome
Side -X- _ O
effects -X- _ O
, -X- _ O
some -X- _ O
serious -X- _ O
, -X- _ O
occur -X- _ O
despite -X- _ O
cytokines -X- _ O
being -X- _ O
endogenous -X- _ O
proteins -X- _ O
, -X- _ O
and -X- _ O
this -X- _ O
therefore -X- _ O
demands -X- _ O
caution -X- _ O
in -X- _ O
attempts -X- _ O
to -X- _ O
introduce -X- _ O
individual -X- _ O
members -X- _ O
into -X- _ O
the -X- _ O
clinic. -X- _ O
This -X- _ O
caution -X- _ O
is -X- _ O
reflected -X- _ O
in -X- _ O
the -X- _ O
relatively -X- _ O
small -X- _ O
number -X- _ O
of -X- _ O
cytokines -X- _ O
currently -X- _ O
approved -X- _ O
by -X- _ O
regulatory -X- _ O
agencies -X- _ O
and -X- _ O
by -X- _ O
the -X- _ O
fact -X- _ O
that -X- _ O
14 -X- _ O
of -X- _ O
the -X- _ O
FDA-approved -X- _ O
preparations -X- _ O
carry -X- _ O
warnings -X- _ O
, -X- _ O
with -X- _ O
10 -X- _ O
being -X- _ O
black -X- _ O
box -X- _ O
warnings -X- _ O
. -X- _ O

